Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis

Title:Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis

Volume: 22 Issue: 29

Author(s): Manolis Vavuranakis, Gerasimos Siasos, Theodoros Zografos, Evangelos Oikonomou, Dimitris Vrachatis, Konstantinos Kalogeras, Theodoros Papaioannou, Michail-Aggelos Kolokathis, Carmen Moldovan and Dimitrios Tousoulis

Affiliation:

Keywords: Transcatheter aortic valve implantation, dual antiplatelet therapy, single antiplatelet therapy, acetylsalicylic acid, clopidogrel, stroke.

Abstract: Background: Transcatheter aortic valve implantation (TAVI) has undeniably earned a prestigious post in the quiver of interventional cardiologists against symptomatic severe aortic stenosis. Cerebrovascular events are listed within the most frequent complications.

Methods: We performed a systematic search of EMBASE, MEDLINE, and the Cochrane library from inception to March 2016 for the following search terms (transcatheter AND antiplatelet) OR (transcatheter AND antithrombotic) to retrieve studies of dual antiplatelet treatment (DAPT) and single antiplatelet treatment (SAPT) in patients after TAVI to study thrombotic, hemorrhagic and cardiovascular events at 30 days post procedure. From a total of 208 records 4 studies met inclusion criteria.

Results: In the included studies, 286 patients were enrolled in the DAPT group and 354 patients in the SAPT group. There was no difference in all-cause mortality, cardiovascular mortality, stroke, and myocardial infraction 30 days post TAVI between DAPT and SAPT. However, patients in the DAPT group had a significantly increased incidence of lethal and major bleeding at 30 days of follow-up and the incidence of the combined end-point of stroke, spontaneous MI, all-cause mortality and major bleeding was significantly higher in the DAPT group in comparison to the SAPT group.

Conclusion: DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria.

Cite this article as:

Vavuranakis Manolis, Siasos Gerasimos, Zografos Theodoros, Oikonomou Evangelos, Vrachatis Dimitris, Kalogeras Konstantinos, Papaioannou Theodoros, Kolokathis Michail-Aggelos, Moldovan Carmen and Tousoulis Dimitrios, Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160601110716